Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
INNOVUS PHARMACEUTICALS, INC. (INNV) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/26/2021 GN InnovAge to Announce Third Quarter 2021 Financial Results and Host Conference Call Monday, May 10, 2021
03/12/2021 GN InnovAge Announces Exercise of Underwriters' Option to Purchase Additional Shares
02/25/2020 15-12G Form 15-12G - Securities registration termination [Section 12(g)]:
02/25/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/25/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/25/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/25/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/25/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/25/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/25/2020 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
02/20/2020 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
02/19/2020 4 ARMISTICE CAPITAL, LLC (10% Owner) has filed a Form 4 on INNOVUS PHARMACEUTICALS, INC.
Txns: Disposed of 300,000 shares @ $0
Disposed of 76,190 options to buy @ $15.75, valued at $1.2M
Disposed of options to buy @ $15.75, valued at $0
Disposed of 431,489 options to buy @ $7.35, valued at $3.2M
Disposed of options to buy @ $7.35, valued at $0
Disposed of 431,489 options to buy @ $8.4, valued at $3.6M
Disposed of options to buy @ $8.4, valued at $0
Disposed of 200,637 options to buy @ $0.001, valued at $200.6
Disposed of options to buy @ $0.001, valued at $0
02/19/2020 4 ARMISTICE CAPITAL, LLC (10% Owner) has filed a Form 4 on INNOVUS PHARMACEUTICALS, INC.
Txns: Disposed of 300,000 shares @ $0
Disposed of 76,190 options to buy @ $15.75, valued at $1.2M
Disposed of options to buy @ $15.75, valued at $0
Disposed of 431,489 options to buy @ $7.35, valued at $3.2M
Disposed of options to buy @ $7.35, valued at $0
Disposed of 431,489 options to buy @ $8.4, valued at $3.6M
Disposed of options to buy @ $8.4, valued at $0
Disposed of 200,637 options to buy @ $0.001, valued at $200.6
Disposed of options to buy @ $0.001, valued at $0
02/14/2020 8-K Quarterly results
02/14/2020 8-K Quarterly results
01/15/2020 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/07/2020 4 LIU VIVIAN H (Director) has filed a Form 4 on INNOVUS PHARMACEUTICALS, INC.
Txns: Granted 10,112 restricted stock units @ $0.89, valued at $9k
01/07/2020 4 Nuhaily Dean (Director) has filed a Form 4 on INNOVUS PHARMACEUTICALS, INC.
Txns: Granted 6,742 restricted stock units @ $0.89, valued at $6k
01/07/2020 4 MIRZA ZIAD (Director) has filed a Form 4 on INNOVUS PHARMACEUTICALS, INC.
Txns: Granted 6,742 restricted stock units @ $0.89, valued at $6k
11/13/2019 10-Q Quarterly Report for the period ended September 30, 2019
10/03/2019 425 Form 425 - Prospectuses and communications, business combinations:
10/02/2019 4 LIU VIVIAN H (Director) has filed a Form 4 on INNOVUS PHARMACEUTICALS, INC.
Txns: Granted 4,286 restricted stock units @ $2.1, valued at $9k
10/02/2019 4 MIRZA ZIAD (Director) has filed a Form 4 on INNOVUS PHARMACEUTICALS, INC.
Txns: Granted 2,858 restricted stock units @ $2.1, valued at $6k
10/02/2019 4 Nuhaily Dean (Director) has filed a Form 4 on INNOVUS PHARMACEUTICALS, INC.
Txns: Granted 2,858 restricted stock units @ $2.1, valued at $6k
09/23/2019 425 Form 425 - Prospectuses and communications, business combinations:
09/18/2019 4 ARMISTICE CAPITAL, LLC (10% Owner) has filed a Form 4 on INNOVUS PHARMACEUTICALS, INC.
Txns: Bought 9,183 shares @ $2.48, valued at $22.8k
Bought 9,000 shares @ $2.65, valued at $23.9k
09/18/2019 8-K Acquisition/merger/asset purchase announced
Docs: "Agreement and Plan of Merger, by and among Aytu BioScience, Inc., Aytu Acquisition Sub, Inc. and Innovus Pharmaceuticals, Inc",
"Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals"
09/18/2019 425 Form 425 - Prospectuses and communications, business combinations:
09/18/2019 3 ARMISTICE CAPITAL, LLC (10% Owner) has filed a Form 3 on INNOVUS PHARMACEUTICALS, INC.
09/13/2019 425 Form 425 - Prospectuses and communications, business combinations:
08/13/2019 10-Q Quarterly Report for the period ended June 30, 2019
08/13/2019 8-K Quarterly results
Docs: "Innovus Pharma Reports Quarterly Revenue for the Second Quarter 2019 of $6.8 million, a 27.7% Increase from Prior Quarter Sales & Marketing Expense as a Percentage of Total Revenue Declined to 41.7% for the three months ended June 30, 2019 Compared with 75.6% in Comparable Period in the Prior Year Reduced Operating Loss by 21% Compared with both the Prior Quarter and Comparable Quarter in the Prior Year SAN DIEGO, August 13, 2019 – Innovus Pharmaceuticals, Inc. , an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women's health and respiratory diseases, announced today its reported results for the second quarter ended June 30, 2019. Financial highlights for the second qua..."
07/24/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/22/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Innovus Pharma Investor Relations"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy